Merck & Co Inc has said that Januvia, its oral, once-daily medicine for type 2 diabetes has shown promise in combating the disease Merck & Co Inc has said that Januvia, its oral, once-daily ...

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug ...

Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

Type 2 diabetes also disproportionately affects ... linagliptin (Tradjenta), saxagliptin (Onglyza), and sitagliptin (Januvia) glucagon-like peptides stimulate your pancreas to produce more insulin ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and role in therapy of vildagliptin for the treatment of type 2 diabetes mellitus were reviewed.

The FDA rejected sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control in adults with type 1 ...

Ghana has become the first country in Africa to take stock of a highly-sort after, efficient drug for Type 2 diabetes patients, Januvia. This was announced by the President of the National ...

Merck already has the world’s biggest selling oral treatment for type 2 diabetes, its DPP-4-based drugs Januvia and Janumet, but it is playing catch-up in the SGLT2 market. The monotherapy and ...

Diabetes has long been lumped into two categories - Type 1, which often appears in childhood, or Type 2, which is associated with obesity and typically develops later in life. But scientists have ...